AbCellera Biologics Total Assets 2022-2021 | ABCL

AbCellera Biologics total assets from 2022 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
AbCellera Biologics Annual Total Assets
(Millions of US $)
2020 $0
AbCellera Biologics Quarterly Total Assets
(Millions of US $)
2021-09-30 $0
2021-06-30 $0
2021-03-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.830B $0.233B
AbCellera Biologics Inc. is a technology company which searches, decodes and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera Biologics Inc. is based in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69